Home / Patient Care / INSPIRE Clinic / Research Studies
Research Studies
INSPIRE Clinic
Culturally Informed Therapy Groups
We invite you to participate in a research study aimed at improving family relations and mental health symptoms. Groups will be offered virtually and in person. Dates/Times TBD.
Psychotherapy groups consist of 5 modules:
- Family/Collectivism
- Psychoeducation
- Religion/Spirituality/Philosophical Beliefs
- Communication Skills
- Problem-Solving Skills
Each of these modules consists of 3 sessions and each session is one hour, once a week.
Inclusion Criteria:
- 18 years or older.
- Person with living experience of psychosis or relative or friend of someone with psychosis.
- Affiliated with the INSPIRE Clinic.
If you are interested in participating, please contact the Principal Investigator, Dr. Olivia Altamirano or inform your INSPIRE Provider. Contact Information: Phone Number: (650) 736-1443, Email: oaltamir@stanford.edu
For complaints, concerns, or Participant's rights, contact: 1-866-680-2906
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia
Stanford researchers are recruiting adults with psychosis for a clinicial trial adding an additional medicine on to their existing antipsychotic treatment. The primary objective for this study is to evaluate the effect of adjunctive valbenazine (an approved FDA medicine, Ingrezza) versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment. If you would like further information or you’re interested in taking part please contact us at wakeham@stanford.edu.
Arise KAR-012 and KAR-013: A Study to Assess Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Stanford researchers are recruiting adults with schizophrenia for a clinical trial adding an additional medicine to their existing antipsychotic treatment. with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of a muscarinic drug adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia. An initial six week trial may be optionally followed by 52 weeks of open-label study. If you would like further information or you’re interested in taking part please contact us at inspire-research@stanford.edu.
Learn More: Arise KAR-012 and KAR-013
Enlighten Youth: Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Stanford researchers are recruiting teen participants with schizophrenia, schizophreniform, or bipolar disorder who are either currently treated with olanzapine, or if treated with another antipsychotic, the subject has had an inadequate response. The purpose of this study is to find out whether a study drug, LYVALBI (an approved FDA medication of olanzapine/samidorphan), is safe and effective in reducing weight gain in teen participants taking antipsychotics. A 52 week trial may be optionally extended to study long term safety. If you would like further information or you’re interested in taking part please contact us at inspire-research@stanford.edu.
pET Scan: Imaging Synapses With [11C] UCB-J in the Human Brain
Stanford researchers are recruiting healthy controls and participants with an onset of schizophrenia within the last 5 years for a basic research study involving a pET scan. The purpose of this study is to utilize the radioactive positron emission tomography (PET) tracer [11C]UCB-J to test the neural synaptic pruning hypothesis of schizophrenia. We are measuring the synaptic density in the living human brain and exploring the theory that the pathogenic process of schizophrenia is the over-exuberant elimination of neural synapses during development. For further information or if you are interested in taking part please contact us at chaepark@stanford.edu.
Peripheral Immune System in Individuals With Schizophrenia
Stanford researchers are recruiting participants who are already participating in Imaging Synapses With [11C] UCB-J in the Human Brain for participation in basic research exploring the role of the complement immune system in the development of schizophrenia. The purpose of this study is to compare immune system proteins found in the blood of patients with and without psychosis, to determine if functional differences are present that may shed light on biochemical and genetic differences in schizophrenia. Participants would do a single blood draw, usually done during the imaging scan. If you would like further information or you’re interested in taking part please contact us at wakeham@stanford.edu.
Epi-Cal Beehive: California Collaborative Network to Promote Data Driven Care and Improve Outcomes in Early Psychosis
Stanford researchers are working with UC Davis to recruit patients with schizophrenia to build a California early psychosis network using a core assessment battery of surveys delivered by iPad during a normal clinical visit. The aim of this study is to measure the Duration of Untreated Psychosis (DUP) and hopefully standardize best practices for first onset of psychosis throughout the state in community settings. The proposed California network will contribute systematically collected outcomes data from community and university early psychosis clinics, to enhance the development of a national early psychosis network, supported by the NIMH EPINET program. If you would like further information or you're interested in taking part please contact your clinician during your regular INSPIRE appointment.
Ketogenic Diet: Can Neural Network Instability in Schizophrenia be Improved With a Very Low Carbohydrate Ketogenic Diet?
Stanford researchers are working with UC San Francisco to recruit patients with schizophrenia, schizoaffective disorder, or bipolar disorder for a study on the impact of a ketogenic diet on mental and physical health. The premise of the work is based on recent evidence that ketogenic diets improve dynamic neural network instability, related to cognitive deficits, aging, metabolic syndrome, and Type 2 diabetes.
Erudite: Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia
Stanford researchers are participating in a study to evaluate the safety and efficacy of luvadaxistat compared with placebo on improving cognitive performance in participants with schizophrenia. This trial is closed to new participants.
Connex: CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
Stanford researchers are participating in a study to evaluate the safety and efficacy of iclepertin compared with placebo on improving cognitive performance in participants with schizophrenia. This trial is closed to new participants.
IMPACT-TD: A prospective multicenter study to characterize the natural history of tardive dyskinesia (TD) and investigate the real-world effectiveness of deutetrabenazine on the multidimensional impact of TD
A prospective multicenter study to characterize the natural history of tardive dyskinesia (TD) and investigate the real-world effectiveness of deutetrabenazine on the multidimensional impact of TD
Stanford researchers are participating in a registry study to follow the natural history of tardive dyskinesia (TD) and optionally to investigate the real-world effectiveness of deutetrabenazine (FDA-approved medicine AUSTEDO) on treating TD. This trial is closed to new participants.
For more information on national research, please visit:
Clinical Trials (dot) gov | Brain & Behavior Research Foundation